Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ABO1009-DP
- Development stage
- Phase 1
- Lead developer
- Abogen Bioscience
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intramuscular
01
Overview
ABO1009-DP is an investigational mRNA vaccine developed specifically to target the Omicron BA.1 sub-lineage (B.1.1.529) of SARS-CoV-2, the virus responsible for COVID-19[2][3][4]. It encodes the receptor-binding domain (RBD) of the spike protein from this variant, aiming to induce both humoral and cellular immune responses against Omicron[2]. The vaccine is administered intramuscularly and has been evaluated as a booster in adults who have previously completed a primary COVID-19 vaccination series[5]. Early clinical studies indicate that ABO1009-DP demonstrates good safety and tolerability as a booster dose, with ongoing trials assessing its immunogenicity and efficacy against evolving Omicron sub-lineages[2][5]. The developer is Suzhou Abogen Biosciences, which has also developed other mRNA vaccines for COVID-19.
- Other names
- SARS-CoV-2 variant (Omicron) mRNA vaccine
02
Targets
Spike-ACE2 PPI (SARS-CoV-2 spike–ACE2 interface)Omicron RBD (SARS-CoV-2 Omicron spike receptor-binding domain)RBD (SARS-CoV-2 spike receptor-binding domain)
Beyond the preview
Go deeper on ABO1009-DP.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ABO1009-DP.